Letter to the Editor

Page 8

Recently published articles about Letter to the Editor

JCP
Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al
Letter to the Editor

July 3, 2023

Bénédicte Nobile, PharmD, PhD, and Philippe Courtet, MD, PhD, continue the discussion of potentially increased suicidal risk with daridorexant, a new hypnotic.
,
JCP
Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link
Letter to the Editor

July 3, 2023

Palagini and colleagues comment on a recent letter that suggested a role for daridorexant, a new hypnotic, in increasing suicide risk.
, , , et al
PCC
Comment on Palinacousis or Auditory Perseverations and COVID-19 Vaccination
Letter to the Editor

June 27, 2023

In this letter to the editor, Amnuay Kleebayoon, PhD, and Viroj Wiwanitkit, MD, comment on a report published recently in the PCC.
,
PCC
Varenicline Use for Cocaine Dependence
Letter to the Editor

May 30, 2023

In this letter to the editor, Abhishek Gupta, MBBS, reviews the latest research on the use of varenicline in cocaine dependence.
PCC
Zoom Dysmorphia and Body Dysmorphic Disorder
Letter to the Editor

April 27, 2023

In this letter to the editor, Tomás Teodoro, MD, MSc, comments on a report recently published in the PCC.
PCC
Neuropsychiatric Manifestations of Mpox
Letter to the Editor

April 18, 2023

Rujittika Mungmunpuntipantip, PhD, and Viroj Wiwanitkit, MD, comment on a report recently published in the PCC.
,
PCC
Lurasidone-Induced Urinary Retention
Letter to the Editor

April 4, 2023

Gregory M. Asnis, MD, comments on a report recently published in the PCC.
PCC
Comment on Huntington’s Disease With Psychotic Features
Letter to the Editor

March 7, 2023

Herwig Lange, MD, comments on a report previously published in the PCC.
PCC
State of the Art of Diagnostics and Genetics in Huntington’s Chorea
Letter to the Editor

March 7, 2023

Mayank Gupta, MD, and Christoph U. Correll, MD, respond to Herwig Lange, MD, regarding their previous case report of a patient with Huntington’s disease.
,
PCC
Buprenorphine Maintenance in the Fentanyl Era
Letter to the Editor

February 14, 2023

Methods to foster patient adherence and physician acceptability of buprenorphine maintenance are needed to incorporate this treatment into primary care for fentanyl users.
,
JCP
Possible Suicidal Risk With Daridorexant
Letter to the Editor

December 7, 2022

Instructions for use of the new anti-insomnia medication daridorexant mention cautious use in patients with history of suicidal behavior. This letter explores the factors that underlie this recommendation for...
, ,
JCP
Pregnancy Outcomes After SGA Exposure: Extracting More From the Data
Letter to the Editor

November 30, 2022

Malathi Perugula, MD, and colleagues call attention to design aspects of a recent study on antipsychotic use in pregnancy.
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe